Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Graft-Versus-Host Disease

Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody


Acute graft-versus-host disease (aGVHD) is a serious complication of allogeneic peripheral blood stem cell transplantation (PBSCT). Patients with severe aGVHD not responding to treatment with steroids have a poor prognosis. We treated four patients with severe aGVHD refractory to steroids with infliximab, a chimeric human/mouse antiTNFα antibody. Patients (CML 2, MM 1, AML 1) developed grade III–IV GVHD at a median of 34 days (range 15–76) after myeloablative PBSCT (two), donor lymphocyte infusion for relapsed CML (one) or non-myeloablative PBSCT (one), respectively. All patients had severe intestinal involvement in addition to skin and/or liver disease and had received treatment with high-dose steroids (four) for a median of 11 days (range 5–17) in addition to CsA (four) and MMF (three). Infliximab (10 mg/kg) was given once a week until clinical improvement. In three of four patients a complete resolution of diarrhea and significant improvement of skin and liver disease were observed. Two patients received one, one patient two and one patient three infliximab infusions. At present two patients are alive >200 days after therapy, one with limited cGVHD. Two patients died, one of progressive malignant disease without GVHD and one of refractory GVHD. Infliximab is apparently an active drug for the treatment of aGVHD. Bone Marrow Transplantation (2001) 28, 47–49.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout


  1. Shlomchik WD, Couzens MS, Bi Tang C et al. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells Science 1999 285: 412–415

    Article  CAS  Google Scholar 

  2. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host-disease: secondary treatment Blood 1991 62: 626–631

    Google Scholar 

  3. Przepiorka D, Kernan NA, Ippoliti C et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease Blood 2000 95: 83–89

    CAS  PubMed  Google Scholar 

  4. Piguet PF, Grau GE, Allet B et al. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease J Exp Med 1987 166: 1280–1289

    Article  CAS  Google Scholar 

  5. Scallon BJ, Moore MA, Trinh H et al. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions Cytokine 1995 7: 251–259

    Article  CAS  Google Scholar 

  6. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease New Engl J Med 1999 340: 1398–1405

    Article  CAS  Google Scholar 

  7. Choi HK, Seeger JD, Kuntz KM . A cost-effectiveness analysis of treatment options for patients with methotrexate resistant rheumatoid arthritis Arthr Rheum 2000 43: 2316–2327

    Article  CAS  Google Scholar 

  8. Couriel D, Hicks K, Ipolitti C . Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients An Rheu Dis 2000 95: (Suppl. 1) Abstr. 537

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kobbe, G., Schneider, P., Rohr, U. et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody. Bone Marrow Transplant 28, 47–49 (2001).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • graft-versus-host disease
  • TNF-α
  • infliximab

This article is cited by


Quick links